 | | Vol. 15.11 – 24 March, 2021 |
| |
|
|
| Researchers revealed that epidermal nerve endings from a subset of sensory nonpeptidergic neurons expressing MrgprD were reduced by the absence of Langerhans cells.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that signal integration occurs through the formation of a ternary Neogenin-Netrin-1-repulsive guidance molecule (NEO1-NET1-RGM) complex, which triggered reciprocal silencing of downstream signaling.
[Cell] |
|
|
|
| Investigators introduced classes of microfabricated 3D frameworks as compliant, multifunctional neural interfaces to spheroids and to assembloids.
[Science Advances] |
|
|
|
| To define the nature of the species giving rise to neuronal damage, the authors investigated the mechanism of action of the main α-synuclein populations that have been observed to form progressively during fibril growth.
[Nature Communications] |
|
|
|
| Scientists demonstrated that mitochondria-lysosome contacts could dynamically form in the soma, axons, and dendrites of human neurons, allowing for their bidirectional crosstalk.
[Nature Communications] |
|
|
|
| The authors showed that Withaferin A protected against loss of dopaminergic neurons, neuroinflammation, and motor deficits in MPTP-induced Parkinson’s disease mouse models.
[Cell Death & Differentiation] |
|
|
|
| Macroautophagy/autophagy plays a critical role in spiral ganglion neurons (SGNs) development, but the effect of autophagy on cisplatin-induced SGN injury is unclear. Scientists found that autophagic flux was activated in SGNs after cisplatin damage.
[Autophagy] |
|
|
|
| The authors showed elevated activation of the mechanistic target of rapamycin kinase (MTOR) pathway in human-derived astrocytes harboring mutant superoxide dismutase 1 (SOD1), which resulted in inhibition of macroautophagy/autophagy, increased cell proliferation, and enhanced astrocyte reactivity.
[Autophagy] |
|
|
|
| The effect was consistent across an overexpression model, neurons from a G2019S knock-in mouse, and human-induced pluripotent stem cell-derived neurons gene-edited to express the G2019S mutation, and the effect was reversed by genetic or pharmacological inhibition of leucine-rich repeat kinase 2 (LRRK2).
[Current Biology] |
|
|
|
| In order to identify potentially novel sites of leptin action, scientists used PhosphoTRAP to molecularly profile leptin-responsive neurons in the hypothalamus and brainstem.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers demonstrated increased binding of a specific GA binding protein B1L (GABPB1L)-isoform–containing complex to the mutant telomerase reverse transcriptase (TERT) promoter. They found that TERT promoter mutant glioblastoma cells, unlike wild-type cells, exhibited a critical near-term dependence on GABPB1L for proliferation.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists presented an engineering approach that addressed several existing shortcomings of brain organoids. By culturing brain organoids with a polycaprolactone scaffold, they were able to modify their shape into a flat morphology.
[Biofabrication] |
|
|
|
|
| Investigators summarize the basic characteristics, adaptive transition, and implications of glioblastoma stem cells in glioblastoma therapy.
[Signal Transduction and Targeted Therapy] |
|
|
|
| The authors describe sex-related differences in neurodegenerative diseases and the blood–brain barrier, whose dysfunction is linked to neurodegenerative disease development and progression.
[APL Bioengineering] |
|
|
|
| Scientists describe the immunosuppressive molecular characteristics of recurrent glioblastoma; clinical trials exploring anti-PD-1/PD-L1 therapy, tumor-specific peptide vaccination, and CAR-T cell therapy; candidate combination strategies; and issues related to strengthening T cell function.
[Cell Death & Disease] |
|
|
|
|
| F. Hoffmann-La Roche Ltd announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington’s disease.
[F. Hoffmann-La Roche Ltd] |
|
|
|
| BERG Health announced with leading cancer centers that the FDA has authorized a Phase II trial in GBM patients in neo-adjuvant settings using BERG’s BPM 31510.
[BERG Health (PR Newswire, LLC.)] |
|
|
|
|
| April 19 – 23, 2021
Virtual |
|
|
|
|
|
| | University of Minnesota Medical Center – Minneapolis, Minnesota, United States |
|
|
|
| | University of California, San Francisco – San Francisco, California, United States |
|
|
|
| | Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| | Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| | Nanyang Technological University – Singapore, Singapore |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
